ArticleJournal of experimental & clinical cancer research : CR2026
SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAcquired resistance remains a major obstacle in molecular-targeted therapy for advanced hepatocellular carcinoma (HCC). This study aimed to elucidate the role and underlying mechanisms of SERPINE2 in mediating lenvatinib resistance by suppressing ferroptosis.
methodsWe analyzed SERPINE2 expression and its clinical prognostic relevance using public databases (TCGA) and clinical samples (tumor tissues and serum) from patients with HCC treated with lenvatinib. By establishing hypoxic and acquired lenvatinib-resistant HCC cell models, combined with subcutaneous xenograft and orthotopic liver cancer mouse models, we systematically evaluated the functional role of SERPINE2 in tumor proliferation, apoptosis, ferroptosis, and lenvatinib resistance in vitro and in vivo. Mechanistic insights were obtained through transcriptome sequencing (RNA-seq), quantitative proteomics, co-immunoprecipitation (Co-IP), nuclear-cytoplasmic fractionation, and measurement of key ferroptosis indicators (lipid ROS, mitochondrial membrane potential, and transmission electron microscopy). Finally, we assessed the therapeutic potential of targeted interventions combining a JAK inhibitor (Ruxolitinib) or NRF2 inhibitor (ML385) with lenvatinib to overcome resistance in vitro and in vivo.
resultsSERPINE2 was markedly upregulated in hypoxic and lenvatinib-resistant HCC models and clinical tissues, correlating with a poor prognosis. Mechanistically, SERPINE2 activates the JAK2/STAT3 signaling pathway, promotes the STAT3-NRF2 interaction, and facilitates NRF2 nuclear translocation. This upregulates the antioxidant enzyme GCLC, which strengthens glutathione synthesis, inhibits lipid peroxidation and ferroptosis, and ultimately confers lenvatinib resistance. Inhibiting SERPINE2, STAT3, or GCLC restored ferroptosis and re-sensitized HCC cells to lenvatinib. Furthermore, the combination treatments exhibited significant synergistic antitumor effects in vitro and in vivo. Clinically, elevated SERPINE2 levels positively correlated with GCLC, predicted worse survival outcomes, and effectively distinguished lenvatinib-resistant patients.
conclusionsThis study established the SERPINE2-JAK2/STAT3-NRF2-GCLC signaling axis as a key mechanism driving ferroptosis resistance and lenvatinib treatment failure. Targeting this axis provides a novel therapeutic strategy for overcoming lenvatinib resistance in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.